CIK 1512848
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 48.89% | 20 |
| Unclassified | 20.05% | 2 |
| Health Care Providers & Services | 14.83% | 1 |
| Health Care Equipment & Supplies | 11.98% | 2 |
| Software | 4.26% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | ARCELLX INC | Unclassified | 19.88% | |
| 2 | CELC | Celcuity Inc. | Health Care | 14.83% |
| 3 | SGP | SpyGlass Pharma, Inc. | Health Care | 10.89% |
| 4 | TRVI | Trevi Therapeutics, Inc. | Health Care | 8.97% |
| 5 | SVRA | Savara Inc | Health Care | 7.60% |
| 6 | GLUE | Monte Rosa Therapeutics, Inc. | Health Care | 7.19% |
| 7 | MBX | MBX Biosciences, Inc. | Health Care | 6.13% |
| 8 | ZBIO | Zenas BioPharma, Inc. | Health Care | 4.47% |
| 9 | COUR | Coursera, Inc. | Information Technology | 4.26% |
| 10 | AUPH | Aurinia Pharmaceuticals Inc. | Health Care | 3.34% |
24/26 names classified · sector 79.9% of weight · industry 79.9% · mkt cap 79.5%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 79.9% of the book is sector-classified (unclassified names shown, never dropped).
Only 4% of book weight classified — the grid is NOT representative of the whole book.
Classified: 3.9% of book weight (2/25 names) · unclassified 96.1%: , CELC, SGP, TRVI, SVRA, GLUE, MBX, ZBIO, COUR, ORIC +13 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | ARCELLX INC | 3,045,262 | $350M | 19.9% | HOLD |
| 2 | CELCCELCUITY INC | 2,285,561 | $261M | 14.8% | TRIM −35% |
| 3 | SGPSPYGLASS PHARMA INC | 7,392,301 | $192M | 10.9% | NEW |
| 4 | TRVITREVI THERAPEUTICS INC | 13,222,228 | $158M | 9.0% | HOLD |
| 5 | SVRASAVARA INC | 24,471,264 | $134M | 7.6% | HOLD |
| 6 | GLUEMONTE ROSA THERAPEUTICS INC | 7,692,298 | $127M | 7.2% | HOLD |
| 7 | MBXMBX BIOSCIENCES INC | 3,614,486 | $108M | 6.1% | HOLD |
| 8 | ZBIOZENAS BIOPHARMA INC | 4,023,219 | $79M | 4.5% | ADD 14% |
| 9 | COURCOURSERA INC | 12,867,769 | $75M | 4.3% | HOLD |
| 10 | AUPHAURINIA PHARMACEUTICALS INC | 3,969,834 | $59M | 3.3% | HOLD |
| 11 | ORICORIC PHARMACEUTICALS INC | 4,118,621 | $52M | 3.0% | HOLD |
| 12 | CRSPCRISPR THERAPEUTICS AG | 1,058,570 | $50M | 2.9% | HOLD |
| 13 | PHATPHATHOM PHARMACEUTICALS INC | 1,960,169 | $22M | 1.2% | HOLD |
| 14 | CVRXCVRX INC | 2,026,083 | $19M | 1.1% | HOLD |
| 15 | KRROKORRO BIO INC | 1,297,893 | $15M | 0.8% | ADD 19% |
| 16 | XFORX4 Pharmaceuticals, Inc. | 3,233,743 | $13M | 0.8% | HOLD |
| 17 | CSBRCHAMPIONS ONCOLOGY INC | 1,713,720 | $10M | 0.6% | HOLD |
| 18 | BDTXBLACK DIAMOND THERAPEUTICS I | 4,448,757 | $9M | 0.5% | HOLD |
| 19 | IVAINVENTIVA SA | 1,462,586 | $8M | 0.5% | HOLD |
| 20 | NKTXNKARTA INC | 3,568,781 | $8M | 0.4% | HOLD |
| 21 | LONALEONABIO INC | 464,398 | $5M | 0.3% | HOLD |
| 22 | SENTI BIOSCIENCES INC | 3,775,615 | $3M | 0.2% | HOLD |
| 23 | MRKRMARKER THERAPEUTICS INC | 1,625,678 | $2M | 0.1% | HOLD |
| 24 | OKURONKURE THERAPEUTICS INC | 478,548 | $2M | 0.1% | HOLD |
| 25 | GOSSGOSSAMER BIO INC | 1,000,000 | $328,500 | 0.0% | TRIM −94% |
| 26 | IMAIMAGENEBIO INC | 50,005 | $250,025 | 0.0% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| ARCELLX INC | 3.7M | 3.7M | 3.7M | 3.0M | 3.0M | 3.0M | $350M |
| CELCCELCUITY INC | 1.3M | 1.3M | 2.3M | 2.1M | 3.5M | 2.3M | $261M |
| SGPSPYGLASS PHARMA INC | — | — | — | — | — | 7.4M | $192M |
| TRVITREVI THERAPEUTICS INC | 11.4M | 11.4M | 13.2M | 13.2M | 13.2M | 13.2M | $158M |
| SVRASAVARA INC | 24.5M | 24.5M | 24.5M | 24.5M | 24.5M | 24.5M | $134M |
| GLUEMONTE ROSA THERAPEUTICS INC | 7.7M | 7.7M | 7.7M | 7.7M | 7.7M | 7.7M | $127M |
| MBXMBX BIOSCIENCES INC | 3.6M | 3.6M | 3.6M | 3.6M | 3.6M | 3.6M | $108M |
| ZBIOZENAS BIOPHARMA INC | 2.6M | 2.6M | 2.7M | 2.7M | 3.5M | 4.0M | $79M |
| COURCOURSERA INC | 12.9M | 12.9M | 12.9M | 12.9M | 12.9M | 12.9M | $75M |
| AUPHAURINIA PHARMACEUTICALS INC | 4.0M | 4.0M | 4.0M | 4.0M | 4.0M | 4.0M | $59M |
| ORICORIC PHARMACEUTICALS INC | 1.6M | 2.2M | 4.1M | 4.1M | 4.1M | 4.1M | $52M |
| CRSPCRISPR THERAPEUTICS AG | 1.6M | 1.6M | 1.6M | 1.1M | 1.1M | 1.1M | $50M |
| PHATPHATHOM PHARMACEUTICALS INC | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | $22M |
| CVRXCVRX INC | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | $19M |
| KRROKORRO BIO INC | 1.1M | 1.1M | 1.1M | 1.1M | 1.1M | 1.3M | $15M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
